Why the study?
Do hemostatic responses to anticoagulant drugs (rivaroxaban and enoxaparin) differ between healthy males and females?
Do hemostatic responses to anticoagulant drugs (rivaroxaban and enoxaparin) differ between healthy males and females?
Healthy females exhibit faster fibrin formation and different hemostatic assay responses to rivaroxaban and enoxaparin compared to males in vitro, suggesting a potential need for gender-specific dosing of anticoagulants.
Findings hypothesis-generating for sex-specific anticoagulant responses; human trials needed before any dosing considerations.
AIM: Recent reports indicate increased mortality in women owing to cardiovascular diseases necessitating more gender-based studies. It is hypothesized that women have variable hemostatic responses to anticoagulant drugs. MATERIALS & METHODS: The hemostatic responses in healthy males (n = 10) and females (n = 10) were evaluated by performing various assays in the presence of anticoagulant drugs. Citrated whole blood from healthy volunteers (n = 20) was supplemented with rivaroxaban (final concentration [FC] = 0.3 µg/ml) and enoxaparin (FC =5 µg/ml). RESULTS: (p = 0.0345) assays in the saline control values. In the plasma system, rivaroxaban at a FC of 0.3 µg/ml and enoxaparin at 5 µg/ml showed a gender-based difference in the Heptest (p = 0.0423). Females showed faster fibrin formation than males. In the plasma system, plasminogen activator inhibitor-1 and domain-dimer assays (American Diagnostica, CT, USA) were performed with domain-dimer showing differences (p = 0.035). In the von Willebrand factor multimers, only band 5 showed differences (p = 0.032). Gender-based differences were observed. CONCLUSION: Careful adjustment of the dosages of anticoagulant drugs may be necessary to avoid bleeding or thrombosis.
No takes yet. Share an insight, caveat, or question.
Iqbal et al. (2012) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: